WO1996004383A1 - Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression - Google Patents
Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression Download PDFInfo
- Publication number
- WO1996004383A1 WO1996004383A1 PCT/US1995/009607 US9509607W WO9604383A1 WO 1996004383 A1 WO1996004383 A1 WO 1996004383A1 US 9509607 W US9509607 W US 9509607W WO 9604383 A1 WO9604383 A1 WO 9604383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- open reading
- gene sequence
- subregion
- region
- reading frames
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 156
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 132
- 230000014509 gene expression Effects 0.000 title claims abstract description 78
- 230000003828 downregulation Effects 0.000 title claims abstract description 51
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 79
- 108091054437 MHC class I family Proteins 0.000 claims abstract description 53
- 102000043129 MHC class I family Human genes 0.000 claims abstract description 52
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 241000701022 Cytomegalovirus Species 0.000 claims description 25
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 21
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 13
- 230000002222 downregulating effect Effects 0.000 claims description 11
- 238000001415 gene therapy Methods 0.000 claims description 11
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 6
- 101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 claims description 4
- 101150030450 IRS1 gene Proteins 0.000 claims description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 abstract description 121
- 208000015181 infectious disease Diseases 0.000 abstract description 29
- 238000012217 deletion Methods 0.000 abstract description 15
- 230000037430 deletion Effects 0.000 abstract description 15
- 230000009467 reduction Effects 0.000 abstract description 13
- 108090000288 Glycoproteins Proteins 0.000 abstract description 11
- 102000003886 Glycoproteins Human genes 0.000 abstract description 10
- 210000002950 fibroblast Anatomy 0.000 abstract description 10
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 abstract description 9
- 101150085955 US11 gene Proteins 0.000 abstract 2
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 abstract 1
- 101100179089 Human herpesvirus 1 (strain 17) ICP22 gene Proteins 0.000 description 53
- 101150053425 US1 gene Proteins 0.000 description 53
- 239000012634 fragment Substances 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 33
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 16
- 101150023587 US10 gene Proteins 0.000 description 14
- 101150084750 1 gene Proteins 0.000 description 13
- 101100427969 Gallid herpesvirus 2 (strain GA) US639 gene Proteins 0.000 description 13
- 241001529936 Murinae Species 0.000 description 13
- 238000001114 immunoprecipitation Methods 0.000 description 13
- 238000000163 radioactive labelling Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000053187 Glucuronidase Human genes 0.000 description 10
- 108010060309 Glucuronidase Proteins 0.000 description 10
- 101150096955 US6 gene Proteins 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 101150036031 gD gene Proteins 0.000 description 9
- 230000008520 organization Effects 0.000 description 9
- 101100504458 Cercopithecine herpesvirus 9 (strain DHV) gI gene Proteins 0.000 description 8
- 101100263193 Gallid herpesvirus 2 (strain GA) US1206 gene Proteins 0.000 description 8
- 101150047715 US3 gene Proteins 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000008488 polyadenylation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 4
- 101710097146 Uncharacterized protein HKLF1 Proteins 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101900071749 Human cytomegalovirus Membrane glycoprotein US3 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 3
- 101150075622 UL80 gene Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JXCKZXHCJOVIAV-UHFFFAOYSA-N 6-[(5-bromo-4-chloro-1h-indol-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid;cyclohexanamine Chemical compound [NH3+]C1CCCCC1.O1C(C([O-])=O)C(O)C(O)C(O)C1OC1=CNC2=CC=C(Br)C(Cl)=C12 JXCKZXHCJOVIAV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108700005001 Cytomegalovirus UL36-38 Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 101710110377 Immediate early protein IE1 Proteins 0.000 description 2
- 101710205424 Immediate-early protein 1 Proteins 0.000 description 2
- -1 J1 I Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101710177509 Major immediate early protein Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 101150030521 gI gene Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- LLGFSTJKTZUOCG-UHFFFAOYSA-N 6-bromo-7-chloro-2,3-dihydro-1H-inden-1-ol Chemical compound BrC=1C(=C2C(CCC2=CC1)O)Cl LLGFSTJKTZUOCG-UHFFFAOYSA-N 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- ZZWZEOLLIYKAFZ-UHFFFAOYSA-M C(C=1C(O)=CC=CC1)(=O)[O-].[Na+].[F] Chemical compound C(C=1C(O)=CC=CC1)(=O)[O-].[Na+].[F] ZZWZEOLLIYKAFZ-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101100371797 Human cytomegalovirus (strain AD169) UL81 gene Proteins 0.000 description 1
- 101900167936 Human cytomegalovirus Capsid scaffolding protein Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010007403 Immediate-Early Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000053208 Porcellio laevis Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150110861 TRM2 gene Proteins 0.000 description 1
- 101150075071 TRS1 gene Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101150039910 UL18 gene Proteins 0.000 description 1
- 101150017804 UL33 gene Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Definitions
- the present invention relates to recombinant mutant human cytomegalovirus (HCMV) which does not down-regulate expression of cellular MHC class I heavy chains upon infection. BACKGROUND OF THE INVENTION
- HCMV Human cytomegalovirus
- HCMV Human cytomegalovirus
- the 230-kb dsDNA genome of HCMV was sequenced (Chee et al., 1 990) and has at least
- open reading frame is defined as the portion of a gene which encodes a string of amino acids and hence may encode a protein.
- the function of some HCMV proteins are known or predicted due to their homology with other viral (esp. herpes simplex virus) and cellular proteins.
- HCMV deletion mutants can be constructed in order to assess their in vitro growth properties (Jones et al., 1991 ; Jones and Muzithras, 1992).
- deletion mutants are defined as human cytomegalovirus mutants which lack regions of the wild-type viral genome.
- This strategy involves site-directed replacement mutagenesis of selected HCMV gene(s) by a prokaryotic reporter gene, usually ⁇ - glucuronidase, although guanosine phosphoribosyltransferase can also be used. In this fashion, the recombinant virus can be isolated only if the replaced viral gene(s) is nonessential.
- the present invention provides recombinant mutant human cytomegaloviruses which do not down-regulate expression of cellular MHC class I heavy chains upon infection. Deletions of gene sequences are made in the region of the genome of the recombinant cytomegalovirus (HCMV) mutant containing open reading frames IRS-1
- the present invention also provides a method of controlling down-regulation of major histocompatibility complex (MHC) class I expression in a cytomegalovirus infected cell which utilizes the recombinant mutant human cytomegaloviruses.
- MHC major histocompatibility complex
- the present invention also provides a vaccine whiGh utilizes the recombinant mutant human cytomegalovirus, as well as a method of preventing or reducing susceptibility to acute cytomegalovirus in an individual by administering an immunogenic amount of the recombinant mutant human cytomegalovirus.
- a live attenuated HCMV vaccine lacking gene sequences in the region of the genome of the recombinant cytomegalovirus (HCMV) mutant containing open reading frames IRS- 1 - US1 1 will elicit a better immune response than one containing this gene region, based on the lack of class I down-regulation by the former. Therefore a virus lacking the region is a superior immunogen.
- the present invention also provides gene therapy vectors in which the HCMV gene involved in the MHC class I heavy chain down-regulation can be incorporated into adenovirus vectors or similar virus based gene therapy vectors to minimize the immune response. This will allow the use of the recombinant adenovirus or similar virus based gene therapy vectors to be used in gene therapy.
- FIG. 1 shows the detection of cell surface MHC class I by immunofluorescence-flow cytometry in HCMV-infected cells.
- Human foreskin fibroblast (HFF) cells were infected with the indicated virus at a multiplicity of infection of 5 PFU/cell for 72 h. At that time, cells were fixed in 1 % paraformaldehyde and stained with primary antibody specific for HLA-A, B, C (W6/32) or control mouse IgG (isotype matched) followed by secondary FITC-conjugated goat anti-mouse IgG.
- Percent positive cells (5x10 3 total) and mean fluorescent intensity (MFI) were calculated on the basis of forward angle light scatter versus log-integrated 90° light scatter using the Immuno Program, Coulter MDADS I.
- FIG. 2 shows expression of MHC class I heavy chains in HCMV wild-type strain AD1 69-infected cells.
- FIG. 2A is a Western blot analysis. HFF cells were uninfected (U) or infected at a multiplicity of infection of 5 PFU/cell. At 24, 48, and 72 h postinfection, total cellular proteins were harvested, electrophoresed through a 1 5% SDS-polyacrylamide gel, electroblotted to nitrocellulose, and probed with TP25.99 murine monoclonal antibody (specific for a non-conformational epitope on MHC class I heavy chains) using an ECL chemiluminescent detection kit (Amersham).
- FIGS. 2B and C are immunoprecipitation analyses.
- HFF cells were uninfected or infected (as above), either in the absence or presence ( + PFA) of phosphonoformate and radiolabeled either for 4 h at late times postinfection (69-73 h) (FIG. 2B) or for 2 h at the indicated time postinfection (FIG. 2C). Proteins were harvested immediately after radiolabeling and class I heavy chains were immunoprecipitated using TP25.99 murine monoclonal antibody.
- FIG. 3 shows organization of recombinant virus genomes.
- FIG. 3A the first line, is a schematic of the overall organization of the HCMV wild-type genome. Unique region sequences are shown by a line, while repeated region sequences are indicated by shaded boxes. Relevant fragments, within the L and S components, are indicated by letter designation (Oram et al., 1 982).
- the second line is an expansion of the wild-type Hind ⁇ -Q., -X, and -V regions of the S component. The significant open reading frames, and their orientation, are shown as open boxes (Chee et al., 1 990). The position of the IR S repeated sequences is indicated by the shaded rectangle.
- FIGS. 3B-I show the genomic organization of the indicated HCMV mutant.
- the first line is the organization of the AD1 69 wild-type genome, the second 6/04383
- - 5 - line represents the organization of relevant sequences of the linearized plasmid used to make the recombinant virus.
- the slanted lines indicate the boundaries of the viral flanking sequences which may be involved in homologous recombination to create the desired mutation.
- the region deleted is indicated by a shaded box below the first line.
- FIG. 3J shows the derivation and organization of RV799.
- the first two lines are the same representations as FIGS. 3B-I, with the third line representing the organization of the relevant sequences of the linearized plasmid used to make RV799 from the RV1 34 parent (second line).
- FIGS. 4A-C show the analysis of heavy chain expression in cells infected with HCMV mutants.
- HFF cells were uninfected (U) or infected with the indicated virus (multiplicity of infection of 5 PFU/cell) and radiolabeled for 4 h at late times postinfection (69-73 h). Proteins were harvested immediately after radiolabeling.
- FIG. 4A is a radiograph of class I heavy chains which were immunoprecipitated using TP25.99 murine monoclonal antibody.
- FIG. 4B is a radiograph of total radiolabeled proteins to verify approximately equivalent radiolabeling efficiency.
- FIG. 4C is a radiograph to verify equal progression through the viral replicative cycle.
- UL80 proteins were immunoprecipitated using anti-assembly protein rabbit polyclonal antiserum.
- FIGS. 5A-C shows immunoprecipitation of class I heavy chains from RV798-, RV799-, RV134-, or AD1 69 wild-type-infected cells.
- HFF cells were uninfected (U) or infected with the indicated virus (multiplicity of infection of 5 PFU/cell) and radiolabeled for 2 h at late times postinfection (71 -73 h). Proteins were harvested immediately after radiolabeling.
- FIG. 5A is a radiograph of class I heavy chains which were immunoprecipitated using TP25.99 murine monoclonal antibody. Equivalent radiolabeling efficiency (FIG. 5B) and progression through the viral replicative cycle (FIG. 5C) were verified as described for FIG. 4B and C.
- FIG. 6 is a radiograph showing the endoglycosidase H sensitivity of class I heavy chains synthesized in RV798-infected cells.
- HFF cells were infected with RV798 (multiplicity of infection of 5 PFU/cell) and radiolabeled for 2 h at early times (6-8 h) or late times
- FIG. 7A-C show the immunoprecipitation of class I heavy chains from RV798-, RV71 81 -, RV7177-, or AD1 69 wild-type-infected cells.
- HFF cells were uninfected (U) or infected with the indicated virus (multiplicity of infection of 5 PFU/cell) and radiolabeled for 2 h at late times postinfection (65-67 h). Proteins were harvested immediately after radiolabeling.
- FIG. 7A is a radiograph of class I heavy chains which were immunoprecipitated using TP25.99 murine monoclonal antibody. Equivalent radiolabeling efficiency (FIG. 7B) and progression through the viral replicative cycle (FIG. 7C) were verified as described for FIG. 4B-C.
- FIG. 8A-D are photographs which show localization of US1 1 gene product (gpUS1 1 ) in infected cells by immunofluorescence.
- HFF cells were uninfected or infected with either AD 1 69 wild-type or RV699 (deleted of the US1 1 gene) at a multiplicity of infection of 5 PFU/cell. After 8 h, uninfected and infected cells were fixed with 4% paraformaldehyde. Some cells were then permeabilized with 0.2% Triton X-100. The primary antibody was rabbit polyclonal antisera raised against a US1 1 fusion protein (Jones and Muzithras, 1 991 ) . Fluorescence was visualized through a Zeiss microscope.
- FIG. 9A-D show analysis of heavy chain expression in cells infected with HCMV mutants at early times postinfection. HFF cells were uninfected (U) or infected with the indicated virus
- FIG. 9A is a radiograph of class I heavy chains which were immunoprecipitated using TP25.99 murine monoclonal antibody.
- FIG. 9B is a radiograph in which, to verify approximately equal infection, the 72-kDa IE 1 immediate-early protein was immunoprecipitated using the murine monoclonal antibody 9221 .
- FIG. 9C is a radiograph of the immunoprecipitation of the cellular transferrin receptor with murine monoclonal antibody Ber-T9 to verify approximately equal expression of this glycoprotein.
- FIG. 9D is a radiograph of total radiolabeled proteins to verify approximately equivalent radiolabeling efficiency.
- FIG. 10 provides a summary of MHC class I heavy chain expression data from HFF cells infected with wild-type and mutant HCMV.
- the first line is the overall organization of the HCMV wild- type genome, and the second line is an expansion of the wild-type Hindlll-Q and -X regions of the S component.
- the ORFs are indicated by an unshaded rectangle; the unlabeled ORF overlapping US4 and US5 is US4.5.
- the deletions within the various HCMV mutants are indicated by the shaded rectangle.
- RV670 is deleted of IRS1 -US9 and
- RV71 86 is deleted of IRS1 -US1 1 .
- SUBST ⁇ TUTE SHEET (RULE 26) regulation results are from immunoprecipitation experiments (using the heavy chain conformation-independent monoclonal antibody, TP25.99) in which HCMV-infected HFF cells were radiolabeled at late times postinfection. The last line shows the location of the two subregions which contain gene(s) which are sufficient for MHC class I heavy chain down-regulation.
- Subregion A contains ORFs US2-US5 (bases 1 931 1 9-1 95607) and subregion B contains ORFs US 10 and US1 1 (bases 1 99083-200360) .
- FIG. 1 1 A-B are Western Blots of cell lines expressing the HCMV US1 1 gene. Uninfected human U373-MG astrocytoma cells stably transformed with a US1 1 expression plasmid were analyzed by Western Blot analysis for MHC class I heavy chain expression (FIG 1 1 A) and for US1 1 expression (FIG. 1 1 B) using the TP25.99 monoclonal antibody and the US1 1 polyclonal antisera, respectively. DESCRIPTION OF THE PREFERRED EMBODIMENTS
- HCMV mutant called RV670 has been constructed which expresses a marker gene ( / S-glucuron ⁇ dase) in place of a group of viral genes.
- a marker gene / S-glucuron ⁇ dase
- MHC major histocompatibility complex
- HCMV infects these cells.
- the present invention does not result in the down-regulation of cellular MHC class I heavy chain protein expression.
- a 7kb region of the HCMV genome which contains genes which are required for down-regulation of heavy chain expression is utilized in the invention.
- virus or another human cytomegalovirus with a deletion of similar genes, can be utilized to produce an effective live vaccine because class I heavy chains are still expressed in RV670-infected cells, as they are in uninfected cells, and therefore viral antigen presentation for the purpose of initiating a cytotoxic T cell response occurs.
- flow cytometry and immunofluorescence experiments confirmed that cell surface expression of class I heavy chains are greatly reduced at late times postinfection in HCMV wild-type strain 81 69 infected HFF cells.
- Subregion A contains ORFs US2-US5 (bases 1 931 1 9- 1 95607). It has been proposed that US2 and US3 encode membrane glycoproteins (Chee et al., 1 990). US3 is a differentially spliced gene which is expressed throughout the viral replicative cycle and encodes a protein with transcriptional transactivating function (Tenney and Colberg-Poley, 1 991 ; Colberg-Poley et al., 1 992; Tenney et al., 1 993; Weston, 1 988) . Several smaller ORFs are also present in this subregion (between the ORFs US3 and US5), but their expression characteristics or functions have not been reported.
- Gretch and Stinski (1990) reported that there is a 1 .0-kb early mRNA transcribed from this region of the HCMV genome, but it was not fine-mapped. It is not yet known which of these genes are involved in heavy chain down-regulation.
- Subregion B which is also sufficient for MHC class I heavy chain reduction, contains the US10 and US1 1 genes (FIG. 10), bases 1 99083-200360.
- US10 expression is not sufficient for down-regulation of heavy chain expression (FIG. 2B).
- the genetic data implicated the US1 1 gene product as being required.
- US1 1 expression is sufficient to cause MHC class I heavy chain down- regulation in stably transformed uninfected cells in the absence of other MCNV proteins (FIG. 1 1 ).
- RNA and protein expression from both of these ORFs begins early and proceeds throughout the course of infection (Jones and Muzithras, 1 991 ); US10 and US1 1 encode glycoproteins of 22-kDa (gpUSI O) and 32-kDa, (gpUS1 1 ) respectively; both glycoproteins have N-linked sugar residues which are completely endoglycosidase H sensitive. These glycoproteins are retained in the endoplasmic reticulum or cis golgi. Consistent with this conclusion is the immunofluorescence data in which gpUS1 1 was not detected on the cell surface, but was detected in the cytoplasm of HCMV-infected cells (FIG. 8) .
- HCMV gpUS1 1 (as well as gpUSI O) are similar to the 25-kDa glycoprotein (E3-1 9K) encoded from the E3 region of adenovirus type 2.
- Ad E3-1 9K is nonessential for viral replication. It has been shown to contain endoglycosidase H- sensitive N-linked sugar residues, be retained in the endoplasmic reticulum, and bind MHC class I heavy chains, thereby preventing their transport to the cell surface 9 (Anderson et al., 1 985; Burgert and Kvist, 1 985).
- Ad E3-1 9K a direct association between gpUS1 1 (or gpUSI O) and class I heavy chains (i.e., by coimmunoprecipitation) was not detected (data not shown).
- US2-US1 1 gene region as the region of the HCMV genome required for down-regulation of MHC class I heavy chains is significant in several respects. As mentioned above, expression from this region of the genome throughout the course of infection acts to interfere with an effective cell mediated immune response. Surface expression of MHC class I molecules is required for antigen presentation to activate and expand cytotoxic T lymphocyte (CTL) precursors populations (Schwartz, 1 985). In addition, they are further required for target recognition by the activated CTLs (Zinkernagel and Doherty, 1 980). In MCMV, CTLs against the major immediate-early protein are protective against lethal infection by this virus (Jonjic et al., 1 988).
- CTL cytotoxic T lymphocyte
- a HCMV mutant deleted of the US2-US1 1 gene region would have this effect since the class I heavy chains are not down-regulated when cells are infected with this mutant. Therefore, a deletion of this region of the viral genome is important in the development of a live HCMV vaccine to induce an effective anti-HCMV immune response.
- ICP47 is expressed in those cells and murine heavy chains are down- regulated when expressed in an HSV-infected human fibroblast system (York et al., 1 994) .
- a pharmaceutical composition may be prepared containing the recombinant HCMV mutant of the present invention in which the genome is devoid of a gene sequence capable of down- regulating MHC Class I expression in infected cells.
- a stabilizer or other appropriate vehicle may be utilized in the pharmaceutical composition.
- the recombinant HCMV mutant of the present invention which is devoid of the gene sequence capable of down-regulating MHC Class I expression may be used in a vaccine for the prevention of cytomegalovirus infections.
- the vaccine comprises an effective amount of the recombinant HCMV mutant in a pharmaceutically acceptable vehicle.
- An adjuvant may be optionally added to the vaccine.
- a method of immunizing an individual against cytomegalovirus may be carried out by administering to the individual an immunogenic amount of the recombinant HCMV mutant of the present invention which is devoid of the gene sequence capable of down-regulating MHC class I expression.
- a method of preventing or reducing susceptibility in an individual to acute cytomegalovirus may be carried out by administering to the individual an immunogenic amount of the recombinant HCMV mutant of the present invention which is devoid of the gene sequence capable of down-regulating MHC class I expression.
- Down-regulation of MHC class I expression in a cytomegalovirus infected cell may be controlled by a method having the steps of identifying a gene sequence capable of down-regulating the major histocompatibility complex and deleting the identified gene sequence from the cytomegalovirus genome.
- the gene sequence involved in the MHC class I heavy chain down-regulation can be incorporated into adenovirus vectors or similar virus based gene therapy vectors to minimize the immune response and allow the use of the vectors in gene therapy.
- One virus based gene therapy vector comprises the gene sequence of the open reading frame of US1 1 .
- Another virus based gene therapy vector comprises the gene sequences of subregions A and B (open reading frames US2-US5 and US10-US1 1 , respectively).
- HFF Human foreskin fibroblast
- Plasmids used for creation of HCMV mutants were constructed using the method described previously (Jones et al., 1 991 ; Jones and Muzithras; 1 992). Generally, the / 5-glucuronidase reporter gene is surrounded on each side by 1 .5-kb of HCMV _ sequences which flank the gene(s) to be deleted from the virus. In each case, the plasmid DNA is linearized with a restriction enzyme which cuts within the prokaryotic backbone prior to transfection. The
- HCMV strain AD1 69 genomic DNA fragments are derived from either pHind-G, pHind-X, or pXba-P which contain the Hind ⁇ -G (bases 1 76844 to 1 95837), -X (bases 1 95837 to 200856), and Xba ⁇ -P (bases 200391 to 206314) DNA fragments, respectively (Oram et al., 1 982; Jones et al., 1 991 ).
- pUS7/US3 contained the 1 .7-kb Pst ⁇ -Pst ⁇
- HCMV fragment (bases 1 96447 to 1 94741 in plBI30 vector [International Biotechnologies, Inc.]) derived from pHind-G and pHind- X.
- pBgdUSI 1 /IRS1 was constructed. Sequentially, this plasmid contained the 1 .8-kb fragment Pst ⁇ -Xba ⁇ fragment (bases 202207 to 200391 , containing US13, US1 2, and US1 1 promoter sequences, from pXba-P), /9-glucuronidase, a 288-b SV40 fragment containing the early and late polyadenylation signals (from pRcCMV [Invitrogen]), and the 1 .7-kb Nco ⁇ -Nco ⁇ fragment (bases 1 89763 to 188062, containing J1 I to IRL1 sequences, from pHind-G).
- pBgdUS1 1 /US2 was constructed. Sequentially, this plasmid contained the 1 .8-kb fragment Pst ⁇ -Xba ⁇ fragment (bases 202207 to 200391 , containing US1 3, US1 2, and US1 1 promoter sequences, from pXba-P), 5-glucuronidase, a 255-b fragment containing the US10 polyadenylation signal (bases 1 99276 to 1 99021 , from pHind-X), and the 1 .3-kb Nhe ⁇ -Apa ⁇ fragment (bases 1 93360 to 1 92033, containing C-terminal US2 to IRS1 sequences, from pHind-G).
- this plasmid contained the 1 .8-kb fragment Pst ⁇ -Xba ⁇ fragment (bases 202207 to 200391 , containing US1 3, US1 2, and US1 1 promoter sequences, from pXba-P), 5-glucuronidase, a 255
- pBgdUS1 1 /US6 was constructed. Sequentially, this plasmid contained the 1 .8-kb Pst ⁇ -Xba ⁇ fragment (bases 202207 to 200391 , containing US1 3, US1 2, and US1 1 promoter sequences, from pXba-P), /9-glucuronidase, and the 1 .5-kb
- Hpa ⁇ -Sst ⁇ fragment bases 1 95589 to 1 94062, containing C-terminal US6 to US3 sequences, from pHind-G
- Replacement of HCMV ORFs US1 1 -US10, or ORF US1 1 (singly), by / 5-glucuronidase (i.e. RV67 and RV699, respectively) were described previously (Jones et al., 1 991 ) .
- pBgdUS9/IRS1 was constructed.
- this plasmid contained the 1 .1 -kb Sal ⁇ -Apa ⁇ fragment (bases 2001 71 to 1 99021 ), the 351 -b SV40 early promoter (from pRcCMV), / 9-glucuronidase, the 288-b SV40 polyadenylation signal fragment, and the 1 .7-kb Nco ⁇ -Nco ⁇ fragment (bases 189763 to
- pBgdUS6/IRS1 was constructed. Sequentially, this plasmid contained the 1 .7-kb Nco ⁇ -Nco ⁇ fragment (bases 188062 to 1 89763, containing IRL1 , J1 I, and IRS1 promoter sequences, from pHind-G), S-glucuronidase, the 255-b fragment containing the US10 polyadenylation signal (bases 1 99276 to 1 99021 , from pHind-X), and the 1 .8-kb Bsm ⁇ -Sa ⁇ fragment (bases 1 96222 to 1 98030, containing US7 to C-terminal US9 sequences, from pHind-X).
- pBgdUS3/US2 was constructed. Sequentially, this plasmid contained the 1 .7-kb Pst ⁇ -Pst ⁇ fragment (bases 1 96447 to 1 94741 ), a 180-b Sma ⁇ -Hae ⁇ fragment containing the HSV-1 gH promoter (McKnight, 1 980), 5-glucuronidase, the 255-b US10 polyadenylation signal fragment, and the 1 .3-kb Nhe ⁇ -Apa ⁇ fragment (bases 1 93360 to 1 92033, containing C-terminal US2 to IRS1 sequences, from pHind-G).
- pBgdUSI was constructed. Sequentially, this plasmid contained the 1 .8-kb Aat ⁇ -Sst ⁇ fragment (bases 190884 to
- this plasmid contained the 1 .7-kb Nco ⁇ -Nco ⁇ fragment (bases 188062 to 189763, containing IRL1 , J1 I, and IRS1 promoter sequences, from pHind-G), ⁇ - glucuronidase, the 255-b fragment containing the US10 polyadenylation signal (bases 199276 to 199021 , from pHind-X), and the 1 .2-kb Nar ⁇ -Xho ⁇ fragment (bases 191830 to 1 93003, containing C-terminal IRS1 and US1 sequences, from pHind-G).
- a reporter gene i.e.,
- this plasmid contained the 1 .8-kb fragment Pst ⁇ -Xba ⁇ fragment (bases 202207 to 200391 , containing US13, US12, and US1 1 promoter sequences, from pXba-P), / 5-glucuronidase, 65-b Nru ⁇ -Apa ⁇ fragment containing the US10 polyadenylation signal (bases 1 99086 to
- 1 .5 ⁇ g of infectious HCMV DNA and 2.5 ⁇ g of linearized plasmid DNA were mixed in the calcium chloride solution (300 ⁇ containing 1 0 mM Tris pH 7.0/250 mM calcium chloride) and chilled on ice.
- the DNA was removed from the ice and 300 ⁇ 2X HeBS pH 6.95 (at room temperature; 1 X HeBS was 19.2 mM HEPES, 137 mM NaCI, 5 mM KCI, 0.8 mM sodium phosphate, 0.1 % dextrose) was added dropwise with gentle mixing. After 1 .5 minutes, the precipitate was placed on ice (to prevent further precipitate from forming).
- the precipitate was mixed with 3x10 6 cells (in suspension) and placed in a 82mm tissue culture plate. After 6 h at 37°C, the media was removed and the cells were shocked with 20% DMSO in 1 X HeBS for 2 minutes. The cells were washed twice with PBS and growth media was added. The media was changed every 4-7 days. After 14 days, viral plaques were observed and the cells were overlaid with 0.5% agarose in DMEM containing 1 50 /vg/ml X-gluc (5-bromo 4-chloro 3-indol 1 -glucuronide;
- Antibodies Rabbit polyclonal antisera reactive with HCMV US1 1 proteins and HCMV UL80 proteins are described previously (Jones et al., 1 991 ; 1 994).
- Murine monoclonal antibody 9221 specific for the HCMV IE1 protein, was purchased from Dupont. Radiolabeling and Immunoprecipitation of Infected Cell Proteins Pulse-chase radiolabeling was done according to standard protocol (Sambrook et al., 1 989). HCMV-infected HFF cells (multiplicity of infection equalled five) was pulse-labeled with 200 /Ci of [ 35 S ] methionine and [ 35 S jcysteine (NEN-DuPont) per ml in methionine/cysteine-free Dulbecco's modified Eagle medium (DMEM) at the indicated time period postinfection.
- DMEM Dulbecco's modified Eagle medium
- the washed immunoprecipitates were boiled in the presence of 2-mercaptoethanol and electrophoresed in denaturing polyacrylamide gels.
- the gels were fixed and soaked in 1 M sodium salicylate fluor (Sambrook et al., 1 989) prior to drying and autoradiography.
- Immunofiuorescence Immunofiuorescence assays were done according to standard protocol (Harlow, 1 989). All procedures were done in 60mm tissue culture plates. Briefly, infected or uninfected HFF cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-1 00 (where indicated) . After adding 3% bovine serum albumin in phosphate-buffered saline, the cells were held overnight at 4°C. The cells were treated sequentially with the following antisera, each for 30 minutes at room temperature: 10% HCMV-negative human serum (to block any Fc receptors); the indicated primary antibody; and FITC- conjugated anti-mouse or anti-rabbit IgG, as appropriate. EXAMPLE 2
- HFF human foreskin fibroblast
- HCMV strain AD1 69 wild-type-infected HFF cells were significantly reduced in the expression of class I heavy chains on their cell surface at late times postinfection (i.e., 72 h) using the conformation- dependent class I monoclonal antibody W6/32 (FIG. 1 ) .
- W6/32 conformation-dependent class I monoclonal antibody W6/32
- FIG. 2A Western analyses using the conformation-independent class I monoclonal antibody (TP25.99), it was demonstrated that the steady state level of class I protein was also reduced at late times postinfection (FIG. 2A). Because viral peptides are presented at the cell surface by class I complexes assembled after infection, we sought to assess the status of class I proteins synthesized at various times postinfection by immunoprecipitation of metabolically radiolabeled proteins. As shown in FIG.
- HCMV deletion mutants representing 18 nonessential ORFs (UL33, UL81 , IRS1 , US1 -US13, US27-US28, and TRS1 ), were screened for heavy chain expression by flow cytometry and immunoprecipitation analyses. Only RV670, a mutant deleted of a 9-kb region within the S component of the HCMV genome (Jones and Muzithras, 1992), did not retain the wild-type down-regulation phenotype (FIG. 4A).
- This mutant was deleted of at least 1 1 ORFs, IRS1 through US1 1 (except for US10), which includes the US6 family of genes (US6-US1 1 ) which putatively encode glycoproteins (Chee et al., 1990).
- US6-US1 1 the US6 family of genes which putatively encode glycoproteins
- two additional independently derived mutants which had the same deletion as RV670 and a new mutant, RV7186, deleted of the entire IRS1 - US1 1 region (FIG. 3) were tested. Each was phenotypically identical to RV670 and stably expressed class I heavy chains.
- HCMV mutants deleted of US6 family ORFs either individually or in groups (Jones and Muzithras, 1 992), and similar deletion mutants within the adjacent IRS1 -US3 region.
- RV71 86 but not the other mutants, is required for the phenotype.
- RV799 a plasmid was designed which upon recombination with the RV1 34 genome would simultaneously delete US2-US1 1 and the ⁇ - glucuronidase expression cassette (FIG. 3).
- the proper RV799 HCMV mutant was isolated as a white plaque in the presence of the ⁇ - glucuronidase substrate, since it was 5-glucuronidase-negative.
- RV799, but not the RV134 parent was phenotypically identical to RV798 (FIG.
- class I heavy chains synthesized in AD169-infected cells were reported to be entirely endoglycosidase H sensitive (Beersma et al., 1993).
- class I heavy chains synthesized in RV798-infected HFF cells were converted to the mature endoglycosidase H-resistant form at a rate similar to those synthesized in uninfected cells.
- these data indicate that MHC class I synthesis, processing, and surface expression are not impaired in cells infected with these HCMV mutants.
- the results indicate that the 7-kb region containing US2-US1 1 genes contain one or more genes required for heavy chain down-regulation by HCMV.
- the region of the HCMV genome deleted in RV35 was from US6-US1 1 , and US2-US1 1 in RV798 (FIG. 3).
- RV35-infected HFF cells MHC class I heavy chains were down-regulated, but in RV798-infected cells they were not (Fig. 4A) .
- This data indicates that one or more genes involved in heavy chain down-regulation maps within the 2-kb subregion from ORF US2 through US5 (subregion A; bases 1 931 1 9-1 95607).
- HCMV replacement mutants RV71 81 and RV71 77 were examined.
- HCMV ORFs IRS1 - US9 and IRS1 -US6 are deleted, respectively, in these mutants; hence, subregion A is absent from both mutants.
- HFF cells at late times postinfection indicated that both mutants retained the ability to efficiently down-regulate class I heavy gene expression (FIG. 7). Therefore, when present in the HCMV genome, gene(s) within subregion A are sufficient for reduction of MHC expression (e.g., RV35), although their presence is not required for the phenotype. Furthermore, the cumulative data indicate that there are no HCMV genes within the identified 7-kb US2-US1 1 region (i.e., the region deleted in RV798) which are absolutely required for efficient heavy chain down-regulation in infected HFF cells, suggesting that gene(s) from another portion of the US2-US1 1 gene region are also sufficient for the phenotype at late times postinfection. Evidence Indicating That the US1 1 Gene Product is Involved in MHC Class I Heavy Chain Down-Regulation In HFF cells infected with mutant RV71 81 , deleted from
- subregion B comprisesd of the US10 and US1 1 genes (bases 1 99083-200360), is involved in reduction of heavy chain expression.
- HCMV mutant RV670 expressed US10 at steady-state levels similar to wild-type and was deleted of all of the other ORFs in the 7-kb US2-US1 1 gene region, but it did not cause down-regulation of MHC class I heavy chains in infected HFF cells (FIGS. 2B and 4A).
- US1 1 encodes a 32-kDa glycoprotein (gpUS1 1 ) containing N-linked, but not O-linked, carbohydrates which are completely sensitive to endoglycosidase H, indicating that the sugars are in the high mannose form.
- gpUS1 1 was detected throughout infection, beginning at very early times (i.e. 3 h) and continuing through late times postinfection. However, levels of gpUS1 1 in the infected cell are most abundant at approximately 8 h postinfection.
- rabbit polyclonal antisera Jones and Muzithras, 1 991
- RV699 is an HCMV mutant which is isogeneic with AD 1 69, except for a deletion of the US1 1 ORF (Jones et al., 1 991 ). In cells fixed and permeabilized at 8 h postinfection, cytoplasmic fluorescence which obscured definition of the nucleus was observed in AD 1 69-infected
- gpUS1 1 is not a cell surface glycoprotein. From the translated DNA sequence, gpUS1 1 is predicted to have hydrophobic domains near its N- and C-termini (Weston and Barrell, 1 986) which are putative signal sequence and transmembrane domains, respectively. Thus, gpUS1 1 is associated with intracytoplasmic membranes, possibly the endoplasmic reticulum. Down-Regulation of MHC Class I Expression at
- HCMV vaccines were prepared using a method described previously (Elek and Stern, 1 974).
- HCMV mutant RV798 was grown on MRC-5 human diploid lung fibroblasts (CCL171 [American Type Culture Collection]) or human foreskin fibroblasts (MRHF).
- the vaccine is administered by subcutaneous inoculation of approximately 10 3 -10 7 plaque forming units into the deltoid region of the upper arm, as described previously (Elek and Stern, 1 974; Gehrz et al., 1 980; Starr et al., 1981 ).
- the US1 1 coding region bases 200360-1 9971 6 [Chee et al., 1 990]
- some non-coding flanking sequences encompassing bases 200391 -1 99683, were cloned into a eukaryotic expression plasmid under the transcriptional control of the constitutive HCMV major immediate-early promoter-enhancer.
- a cytosolic herpes simplex virus protein inhibits antigen presentation to CD8 + T lymphocytes. Cell 77:525-
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31535/95A AU709552B2 (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
EP95927533A EP0775209A1 (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
NZ290718A NZ290718A (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus hcmv gene region involved in down-regulation of mhc class i heavy chain expression |
CA002195668A CA2195668C (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
JP50665896A JP4036469B2 (en) | 1994-07-29 | 1995-07-28 | Identification of the human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
MXPA/A/1997/000710A MXPA97000710A (en) | 1994-07-29 | 1997-01-28 | Identification of a region of the human citomegalovirus gene involved in the decreasing regulation of the expression of the heavy chain of the main complex of histocompatibility clas |
NO970369A NO970369L (en) | 1994-07-29 | 1997-01-28 | Identification of a human cytomegalovirus gene region involved in downregulation of MHC class 1 heavy chain expression |
FI970351A FI970351A0 (en) | 1994-07-29 | 1997-01-28 | Identification of a human cytomegalovirus gene region involved in the reduction of MHC class I heavy chain expression |
KR1019970700611A KR970704883A (en) | 1994-07-29 | 1997-01-29 | Identification of human cytomegalovirus gene regions involved in down-regulation of MHC class I heavy chain expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,696 US5846806A (en) | 1994-07-29 | 1994-07-29 | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US08/282,696 | 1994-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004383A1 true WO1996004383A1 (en) | 1996-02-15 |
Family
ID=23082718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/009607 WO1996004383A1 (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
PCT/US1995/009799 WO1996004384A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/009799 WO1996004384A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Country Status (11)
Country | Link |
---|---|
US (6) | US5846806A (en) |
EP (2) | EP0775209A1 (en) |
JP (2) | JP4036469B2 (en) |
KR (2) | KR970704884A (en) |
AU (2) | AU709552B2 (en) |
CA (3) | CA2195668C (en) |
FI (2) | FI970352A (en) |
MX (1) | MX9700676A (en) |
NO (2) | NO970369L (en) |
NZ (2) | NZ290718A (en) |
WO (2) | WO1996004383A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032605A1 (en) * | 1996-03-08 | 1997-09-12 | Massachusetts Institute Of Technology | Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases |
WO1998031813A1 (en) * | 1997-01-17 | 1998-07-23 | Roche Diagnostics Gmbh | Inhibitors of antigen presentation by mhc class i molecules |
WO1998047914A2 (en) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gene from the human cytomegalovirus (hcmv) |
WO1999036562A1 (en) * | 1998-01-14 | 1999-07-22 | Human Gene Therapy Research Institute | Nucleotide expression systems with reduced immunogenicity for use in gene therapy |
EP0966301A1 (en) * | 1996-07-31 | 1999-12-29 | Ortho Pharmaceutical Corporation | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
KR20050093003A (en) * | 2004-03-17 | 2005-09-23 | 이재본 | Micro turbine generator |
WO2008095677A1 (en) | 2007-02-07 | 2008-08-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Recombinant antigens of human cytomegalovirus (hcmv) |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US9249427B2 (en) | 2010-05-14 | 2016-02-02 | Oregon Health & Science University | Recombinant HCMV and RHCMV vectors and uses thereof |
US9862972B2 (en) | 2011-06-10 | 2018-01-09 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US10316334B2 (en) | 2013-03-05 | 2019-06-11 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
US10428118B2 (en) | 2014-07-16 | 2019-10-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
US11091779B2 (en) | 2015-02-10 | 2021-08-17 | Oregon Health & Science University | Methods and compositions useful in generating non canonical CD8+ T cell responses |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100008A (en) * | 1998-09-14 | 2000-08-08 | Ppg Industries Ohio, Inc. | Positive photoresist with improved contrast ratio and photospeed |
WO2000046361A1 (en) * | 1999-02-02 | 2000-08-10 | Oregon Health Sciences University | Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells |
WO2002018954A2 (en) | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US20030118568A1 (en) * | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
WO2009073330A2 (en) * | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3697806A4 (en) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010966A1 (en) * | 1988-05-09 | 1989-11-16 | The Children's Hospital, Incorporated | Vectors encoding hcmv glycoprotein and expression products |
EP0521427A1 (en) * | 1991-07-05 | 1993-01-07 | American Cyanamid Company | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058598A (en) * | 1974-10-18 | 1977-11-15 | Harold Stern | Cytomegalovirus attenuation method and vaccine |
US4689225A (en) * | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
WO1988010311A1 (en) * | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
-
1994
- 1994-07-29 US US08/282,696 patent/US5846806A/en not_active Expired - Fee Related
-
1995
- 1995-06-02 US US08/459,586 patent/US5720957A/en not_active Expired - Fee Related
- 1995-06-02 US US08/458,544 patent/US5753476A/en not_active Expired - Fee Related
- 1995-07-28 CA CA002195668A patent/CA2195668C/en not_active Expired - Fee Related
- 1995-07-28 WO PCT/US1995/009607 patent/WO1996004383A1/en not_active Application Discontinuation
- 1995-07-28 JP JP50665896A patent/JP4036469B2/en not_active Expired - Fee Related
- 1995-07-28 EP EP95927533A patent/EP0775209A1/en not_active Withdrawn
- 1995-07-28 NZ NZ290718A patent/NZ290718A/en unknown
- 1995-07-28 AU AU31535/95A patent/AU709552B2/en not_active Ceased
- 1995-07-31 MX MX9700676A patent/MX9700676A/en unknown
- 1995-07-31 WO PCT/US1995/009799 patent/WO1996004384A1/en not_active Application Discontinuation
- 1995-07-31 AU AU32745/95A patent/AU708983B2/en not_active Ceased
- 1995-07-31 EP EP95929364A patent/EP0772681A1/en not_active Withdrawn
- 1995-07-31 NZ NZ291571A patent/NZ291571A/en unknown
- 1995-07-31 CA CA002328638A patent/CA2328638A1/en not_active Abandoned
- 1995-07-31 CA CA002196207A patent/CA2196207C/en not_active Expired - Fee Related
- 1995-07-31 US US08/509,214 patent/US5843458A/en not_active Expired - Fee Related
- 1995-07-31 JP JP8506737A patent/JPH10506268A/en not_active Ceased
-
1997
- 1997-01-28 NO NO970369A patent/NO970369L/en not_active Application Discontinuation
- 1997-01-28 NO NO970370A patent/NO970370L/en not_active Application Discontinuation
- 1997-01-28 FI FI970352A patent/FI970352A/en unknown
- 1997-01-28 FI FI970351A patent/FI970351A0/en unknown
- 1997-01-29 KR KR1019970700612A patent/KR970704884A/en not_active Application Discontinuation
- 1997-01-29 KR KR1019970700611A patent/KR970704883A/en not_active Application Discontinuation
- 1997-10-07 US US08/946,598 patent/US5906935A/en not_active Expired - Fee Related
-
1998
- 1998-03-16 US US09/039,802 patent/US5908780A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010966A1 (en) * | 1988-05-09 | 1989-11-16 | The Children's Hospital, Incorporated | Vectors encoding hcmv glycoprotein and expression products |
EP0521427A1 (en) * | 1991-07-05 | 1993-01-07 | American Cyanamid Company | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
Non-Patent Citations (7)
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032605A1 (en) * | 1996-03-08 | 1997-09-12 | Massachusetts Institute Of Technology | Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases |
EP0966301A1 (en) * | 1996-07-31 | 1999-12-29 | Ortho Pharmaceutical Corporation | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
US6033671A (en) * | 1996-07-31 | 2000-03-07 | Ortho Mcneil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of MHC class I heavy chain expression |
EP0966301A4 (en) * | 1996-07-31 | 2001-09-05 | Ortho Pharma Corp | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
WO1998031813A1 (en) * | 1997-01-17 | 1998-07-23 | Roche Diagnostics Gmbh | Inhibitors of antigen presentation by mhc class i molecules |
WO1998047914A2 (en) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gene from the human cytomegalovirus (hcmv) |
WO1998047914A3 (en) * | 1997-04-18 | 1999-03-11 | Boehringer Mannheim Gmbh | Us6 gene from the human cytomegalovirus (hcmv) |
WO1999036562A1 (en) * | 1998-01-14 | 1999-07-22 | Human Gene Therapy Research Institute | Nucleotide expression systems with reduced immunogenicity for use in gene therapy |
KR20050093003A (en) * | 2004-03-17 | 2005-09-23 | 이재본 | Micro turbine generator |
WO2008095677A1 (en) | 2007-02-07 | 2008-08-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Recombinant antigens of human cytomegalovirus (hcmv) |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2550362A2 (en) * | 2010-03-25 | 2013-01-30 | Oregon Health and Science University | Cmv glycoproteins and recombinant vectors |
EP2550362A4 (en) * | 2010-03-25 | 2013-05-29 | Univ Oregon Health & Science | Cmv glycoproteins and recombinant vectors |
US9541553B2 (en) | 2010-03-25 | 2017-01-10 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
EP3187585A1 (en) * | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
US10101329B2 (en) | 2010-03-25 | 2018-10-16 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US9249427B2 (en) | 2010-05-14 | 2016-02-02 | Oregon Health & Science University | Recombinant HCMV and RHCMV vectors and uses thereof |
US11266732B2 (en) | 2010-05-14 | 2022-03-08 | Oregon Health & Science University | Recombinant HCMV and RHCMV vectors and uses thereof |
US9982241B2 (en) | 2010-05-14 | 2018-05-29 | Oregon Health & Science University | Recombinant HCMV and RHCMV vectors and uses thereof |
US9862972B2 (en) | 2011-06-10 | 2018-01-09 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US10760097B2 (en) | 2011-06-10 | 2020-09-01 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US10316334B2 (en) | 2013-03-05 | 2019-06-11 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
US10428118B2 (en) | 2014-07-16 | 2019-10-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
US10995121B2 (en) | 2014-07-16 | 2021-05-04 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
US11692012B2 (en) | 2014-07-16 | 2023-07-04 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
US11091779B2 (en) | 2015-02-10 | 2021-08-17 | Oregon Health & Science University | Methods and compositions useful in generating non canonical CD8+ T cell responses |
US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
US11305015B2 (en) | 2016-10-18 | 2022-04-19 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Also Published As
Publication number | Publication date |
---|---|
JPH10506268A (en) | 1998-06-23 |
NO970370D0 (en) | 1997-01-28 |
NO970369D0 (en) | 1997-01-28 |
AU709552B2 (en) | 1999-09-02 |
AU3153595A (en) | 1996-03-04 |
CA2195668C (en) | 2004-09-21 |
CA2196207A1 (en) | 1996-02-15 |
FI970352A0 (en) | 1997-01-28 |
US5846806A (en) | 1998-12-08 |
AU3274595A (en) | 1996-03-04 |
JP4036469B2 (en) | 2008-01-23 |
NO970369L (en) | 1997-03-21 |
EP0772681A1 (en) | 1997-05-14 |
KR970704883A (en) | 1997-09-06 |
CA2196207C (en) | 2002-04-30 |
KR970704884A (en) | 1997-09-06 |
US5753476A (en) | 1998-05-19 |
FI970352A (en) | 1997-01-28 |
NZ290718A (en) | 1999-03-29 |
CA2195668A1 (en) | 1996-02-15 |
US5843458A (en) | 1998-12-01 |
US5906935A (en) | 1999-05-25 |
MX9700710A (en) | 1997-09-30 |
NO970370L (en) | 1997-03-24 |
FI970351A (en) | 1997-01-28 |
US5908780A (en) | 1999-06-01 |
JPH10503378A (en) | 1998-03-31 |
AU708983B2 (en) | 1999-08-19 |
NZ291571A (en) | 1999-01-28 |
CA2328638A1 (en) | 1996-02-15 |
MX9700676A (en) | 1997-04-30 |
US5720957A (en) | 1998-02-24 |
EP0775209A1 (en) | 1997-05-28 |
FI970351A0 (en) | 1997-01-28 |
WO1996004384A1 (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5846806A (en) | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression | |
WO1996004384A9 (en) | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression | |
Jones et al. | Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains | |
Jones et al. | Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains | |
Mocarski et al. | A deletion mutant in the human cytomegalovirus gene encoding IE1 (491aa) is replication defective due to a failure in autoregulation. | |
Hunt et al. | Marek's disease virus down-regulates surface expression of MHC (B Complex) Class I (BF) glycoproteins during active but not latent infection of chicken cells | |
US6207168B1 (en) | Vaccine composition for herpes simplex virus and methods of using | |
Kaye et al. | The UL16 gene of human cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro | |
EP0966301B1 (en) | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression | |
McVoy et al. | Repair of a mutation disrupting the guinea pig cytomegalovirus pentameric complex acquired during fibroblast passage restores pathogenesis in immune-suppressed guinea pigs and in the context of congenital infection | |
Tischer et al. | High-level expression of Marek's disease virus glycoprotein C is detrimental to virus growth in vitro | |
JP5469444B2 (en) | GM-negative EHV-mutant without heterologous elements | |
US8877211B2 (en) | Bovine herpes virus vaccine with multiple mutations | |
AU733195B2 (en) | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression | |
KHATTAR et al. | Identification and characterization of a bovine herpesvirus-1 (BHV-1) glycoprotein gL which is required for proper antigenicity, processing, and transport of BHV-1 glycoprotein gH | |
Ata et al. | Development and characterization of ORF68 negative equine herpes virus type–1, Ab4p strain | |
US11591373B2 (en) | HCMV vaccine strain | |
MXPA97000710A (en) | Identification of a region of the human citomegalovirus gene involved in the decreasing regulation of the expression of the heavy chain of the main complex of histocompatibility clas | |
Drolet et al. | Glycoprotein C of herpes simplex virus type 1 is required to cause keratitis at low infectious doses in intact rabbit corneas | |
McVoy et al. | JVI Accepted Manuscript Posted Online 15 June 2016 J. Virol. doi: 10.1128/JVI. 00320-16 Copyright© 2016, American Society for Microbiology. All Rights Reserved. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194425.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2195668 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 290718 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995927533 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/000710 Country of ref document: MX Ref document number: 970351 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970700611 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1995927533 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970700611 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970700611 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995927533 Country of ref document: EP |